Revolution Medicines’ Daraxonrasib Achieves Unprecedented Survival Benefit in Pancreatic Cancer, Signaling New Era for RAS-Targeted Therapies
Revolution Medicines, a leading biotechnology company, announced on Monday groundbreaking results from its highly anticipated Phase 3 clinical trial for daraxonrasib, an investigational drug targeting RAS mutations in pancreatic cancer.…
